4 results about "Gastric Disorders" patented technology

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.